Neoplastic transformation is a multistep process that requires the deregulation of key cellular pathways that control the expansion and the differentiation of progenitor cells. The EVI1 oncogene is inappropriately activated in many tissues resulting in aggressive solid and hematopoietic cancers. The mechanism by which EVI1 operates in the transformation of tissues of different histology is not clear. The overall goal of the proposal that was funded 3 years ago was to determine how EVI1 confers to the cell the ability to escape the control of several cellular pathways including differentiation and proliferation and how it contributes to cell transformation. These studies have shown that EVI1 interacts with master regulatory proteins to disrupt cell cycling, cell proliferation, and normal differentiation. During the prior funding cycle, we have also determined that EVI1 interacts with several transcription coregulators and protein modifiers, which post-translationally modify EVI1 by reversible acetylation or sumoylation. More importantly, by using point mutations we have established that specific interactions with these modifiers are required to alter proliferation and differentiation of primary normal cells by EVI1 and to induce immortalization or transformation. Therefore, we propose that the ability of EVI1 to disrupt multiple pathways is the basis of the very aggressive phenotype characteristic of EVI1-positive cancers. We also propose that EVI1 must be post-translationally modified in order to interact with key cell regulators and induce cell transformation. We determined that EVI1 modifications are required for the assembly of EVI1 in discrete nuclear speckles and we propose that these speckles are centers of EVI1 activity. Therefore, it is likely that disruption of EVI1 modification will impair the ability of EVI1 to alter at least one of these pathways, leading to attenuated or delayed neoplastic transformation. This competing renewal has two overall goals: to identify and analyze multi-protein complexes in which EVI1 participates and to determine which protein-modifications are required to alter proliferation and differentiation.
The specific aims of the proposal are: 1. To characterize EVI1 sumoylation and acetylation and to define their role in transcription regulation. 2. To identify the components and the functions of the nuclear EVI1 multiprotein complexes. 3. To characterize the sumoylation and acetylation of EVI1 in vivo and to define their role in EVI1- induced transformation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA096448-08
Application #
7459874
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Mufson, R Allan
Project Start
2001-09-24
Project End
2010-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
8
Fiscal Year
2008
Total Cost
$281,077
Indirect Cost
Name
University of Illinois at Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Chicago
State
IL
Country
United States
Zip Code
60612
Senyuk, Vitalyi; Premanand, Kavitha; Xu, Peng et al. (2011) The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA. PLoS One 6:e20793
Dickstein, Jerome; Senyuk, Vitalyi; Premanand, Kavitha et al. (2010) Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci U S A 107:9783-8
Laricchia-Robbio, Leopoldo; Premanand, Kavitha; Rinaldi, Ciro R et al. (2009) EVI1 Impairs myelopoiesis by deregulation of PU.1 function. Cancer Res 69:1633-42
Senyuk, Vitalyi; Rinaldi, Ciro Roberto; Li, Donglan et al. (2009) Consistent up-regulation of Stat3 Independently of Jak2 mutations in a new murine model of essential thrombocythemia. Cancer Res 69:262-71
Cattaneo, Francesca; Nucifora, Giuseppina (2008) EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. J Cell Biochem 105:344-52
Senyuk, Vitalyi; Sinha, Kislay K; Li, Donglan et al. (2007) Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis. Cancer Res 67:5658-66
Li, Donglan; Sinha, Kislay K; Hay, Maher A et al. (2007) RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function. J Biol Chem 282:13542-51
Nucifora, Giuseppina; Laricchia-Robbio, Leopoldo; Senyuk, Vitalyi (2006) EVI1 and hematopoietic disorders: history and perspectives. Gene 368:1-11
Mikhail, Fady M; Sinha, Kislay K; Saunthararajah, Yogen et al. (2006) Normal and transforming functions of RUNX1: a perspective. J Cell Physiol 207:582-93
Saunthararajah, Yogen; Boccuni, Piernicola; Nucifora, Giuseppina (2006) Combinatorial action of RUNX1 and PU.1 in the regulation of hematopoiesis. Crit Rev Eukaryot Gene Expr 16:183-92

Showing the most recent 10 out of 15 publications